EGFR and ameloblastoma: Considering that MAPK/ERK signaling can be activated by stimulation of transmembrane receptors, including EGFR, and that overexpression of EGFR had previously been reported in ameloblastomas, when the investigators detected ameloblastoma cultured cells resistant to EGFR-targeted inhibition they screened these cells for BRAF p.V600E mutation [9].